Acute myelogenous leukemia M5b developed during clinical remission of Castleman disease.
Castleman disease (CD) is a rare heterogeneous lymphoproliferative disease characterized by clinical symptoms due to an excess of interleukin-6 (IL-6) or IL-6-like activity. We describe the first case of CD associated with acute myelogenous leukemia (AML). A 55-year-old man presented with skin rash on his face and multiple cervical lymphadenopathy. The results of examination of his lymph node biopsy specimen led to a diagnosis of CD. The symptoms resolved after the administration of prednisolone. Three years after the onset of CD, the patient's white blood cell count had increased to 63.4 x 10(9)/L. His bone marrow aspirate showed that approximately 80% of cells were leukemic, including well-differentiated monocytic cells A diagnosis of AML M5b was made. The patient died of invasive pulmonary aspergillosis after chemotherapy.
Tomonari
Akira
A
Department of Hematology/Oncology, The Institute of Medical Science, The University of Tokyo, Japan. atomonar@ims.u-tokyo.ac.jp
Shirafuji
Naoki
N
Tojo
Arinobu
A
Iseki
Tohru
T
Ooi
Jun
J
Komiya
Itaru
I
Tani
Kenzaburo
K
Asano
Shigetaka
S
D018931:Antineoplastic Agents, Hormonal / Q000627:therapeutic use; D001853:Bone Marrow / Q000473:pathology; D005871:Castleman Disease / Q000150:complications* / Q000188:drug therapy / Q000473:pathology; D017809:Fatal Outcome; D006801:Humans; D007948:Leukemia, Monocytic, Acute / Q000175:diagnosis / Q000188:drug therapy / Q000209:etiology*; D008198:Lymph Nodes / Q000473:pathology; D008297:Male; D008875:Middle Aged; D011239:Prednisolone / Q000627:therapeutic use; D012074:Remission Induction
D018931:Antineoplastic Agents, Hormonal; D011239:Prednisolone